Tate & Lyle (LSE:TATE)'s long history as an independent London-listed ingredients company is drawing to a close. The FTSE 250 group is in the final stages of a recommended all-cash Takeover by US rival Ingredion, and the deal has now cleared one of its most important hurdles: Shareholder approval. On 28 July 2026, Tate & Lyle (LSE:TATE) investors voted overwhelmingly in favour of the £2.7 billion offer, with more than 98% of votes cast supporting the scheme at both the court-convened meeting and the general meeting. What began as an approach earlier in the year has moved decisively into the endgame.
The terms are straightforward. Ingredion is offering 595 pence per share in cash, valuing Tate & Lyle's Equity at about £2.7 billion (roughly $3.6 billion) and giving an Enterprise value of around £3.7 billion once Debt is included. For shareholders, the all-cash structure removes any exposure to the combined group's future share performance and crystallises a premium to the undisturbed price — a clean exit that the board unanimously recommended.
From acquirer to target
There is a certain irony in Tate & Lyle finding itself on the receiving end of a takeover. Only recently the company reshaped itself into a pure-play speciality food and beverage ingredients business, having sold control of its Commodity sweeteners arm and then, in a transformational move, acquired the US speciality ingredients maker CP Kelco in a deal completed in 2024. That Acquisition added pectin and speciality gums and was meant to accelerate Tate & Lyle's shift towards higher-margin solutions in categories such as beverages, dairy and bakery. Ingredion's swoop effectively folds that enlarged, more speciality-focused Tate & Lyle into a still-larger global platform.
The strategic rationale from Ingredion's side is scale. The combined Business would generate Revenue of roughly $9.9 billion with adjusted EBITDA of around $1.8 billion, and management has pointed to cost synergies of about $130 million a year by 2030. Bringing together two complementary ingredient portfolios would create one of the world's largest suppliers of speciality and texturising ingredients to food and drink manufacturers, at a time when producers are reformulating products to cut sugar, add fibre and clean up labels.
What still has to happen
Shareholder approval is a milestone, not the finish line. Completion is expected in the second half of 2027 and remains conditional on antitrust clearances in multiple jurisdictions and on the sanction of the UK High Court. That regulatory timetable is the principal source of remaining uncertainty. Competition authorities scrutinise deals that combine large suppliers in overlapping categories, and there is always a possibility of required divestments or extended reviews. Until the conditions are satisfied, both companies continue to operate independently.
For Tate & Lyle shareholders, the Investment question has largely shifted from operational performance to deal completion. With the price fixed at 595 pence, the shares now trade primarily as a function of the probability and timing of the transaction closing, rather than on trading updates or ingredient-market trends. The main risks are that regulators block or heavily condition the deal, or that the long gap to expected completion in late 2027 ties up Capital that could be deployed elsewhere. A collapse of the transaction would return the focus abruptly to Tate & Lyle's standalone prospects and the integration of CP Kelco.
Investors will watch the sequence of antitrust decisions across the US, UK, Europe and other markets, any conditions attached, and the court process. Barring a regulatory setback, this is a takeover moving steadily towards conclusion — the end of a storied British name as an independent public company, and its absorption into a transatlantic ingredients champion. The headline framing of a deal entering its final act is, on the evidence, accurate.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...